Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
NKTR Nektar Therapeutics	$26.91 +0.7%	$21.76	$6.45 ▼ $37.38	$511.76M	0.95	853,844 shs	485,016 shs
PCRX Pacira BioSciences	$25.01 -0.7%	$23.43	$12.61 ▼ $27.64	$1.12B	0.48	805,691 shs	237,118 shs
SUPN Supernus Pharmaceuticals	$42.68 +1.6%	$34.75	$29.16 ▼ $43.73	$2.39B	0.74	637,759 shs	629,893 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
NKTR Nektar Therapeutics	-2.59%	+13.22%	+7.14%	+181.63%	+33.93%
PCRX Pacira BioSciences	+1.21%	+1.53%	+16.67%	-3.63%	+80.19%
SUPN Supernus Pharmaceuticals	-2.30%	+1.84%	+29.87%	+28.72%	+22.77%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	4.2283 of 5 stars	3.4	4.0	0.0	4.2	3.1	1.7	0.0
PCRX Pacira BioSciences	3.467 of 5 stars	2.4	1.0	0.0	3.9	3.2	2.5	0.6
SUPN Supernus Pharmaceuticals	2.1499 of 5 stars	1.3	2.0	0.0	4.1	2.4	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRX Forest Road Acquisition	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	228.28% Upside
PCRX Pacira BioSciences	2.71	Moderate Buy	$30.83	23.31% Upside
SUPN Supernus Pharmaceuticals	2.67	Moderate Buy	$41.00	-3.95% Downside

Current Analyst Ratings Breakdown

Latest FRX, SUPN, PCRX, and NKTR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	PCRX Pacira BioSciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/6/2025	SUPN Supernus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$42.00 ➝ $46.00
7/30/2025	SUPN Supernus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$42.00
7/25/2025	PCRX Pacira BioSciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
NKTR Nektar Therapeutics	$74.93M	6.83	N/A	N/A	($1.27) per share	-21.19
PCRX Pacira BioSciences	$700.97M	1.60	$4.33 per share	5.77	$16.86 per share	1.48
SUPN Supernus Pharmaceuticals	$661.82M	3.62	$4.14 per share	10.31	$18.97 per share	2.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	-$118.96M	-$8.80	N/A	N/A	N/A	-163.17%	-631.43%	-58.21%	11/6/2025 (Estimated)
PCRX Pacira BioSciences	-$99.56M	-$2.78	N/A	9.73	N/A	-18.08%	13.29%	6.61%	11/5/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.15	37.12	29.64	N/A	9.70%	14.22%	10.82%	11/3/2025 (Estimated)

Latest FRX, SUPN, PCRX, and NKTR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	NKTR Nektar Therapeutics	-$3.13	-$2.95	+$0.18	-$2.95	$9.42 million	$11.18 million
8/5/2025	Q2 2025	PCRX Pacira BioSciences	$0.73	$0.74	+$0.01	-$0.11	$183.11 million	$181.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRX Forest Road Acquisition	N/A	0.37	0.37
NKTR Nektar Therapeutics	N/A	2.61	2.61
PCRX Pacira BioSciences	0.50	2.38	1.91
SUPN Supernus Pharmaceuticals	N/A	2.58	2.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FRX Forest Road Acquisition	N/A
NKTR Nektar Therapeutics	75.88%
PCRX Pacira BioSciences	99.73%
SUPN Supernus Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
FRX Forest Road Acquisition	N/A
NKTR Nektar Therapeutics	5.25%
PCRX Pacira BioSciences	6.40%
SUPN Supernus Pharmaceuticals	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
NKTR Nektar Therapeutics	220	19.02 million	18.31 million	Optionable
PCRX Pacira BioSciences	720	44.93 million	42.06 million	Optionable
SUPN Supernus Pharmaceuticals	580	56.07 million	51.14 million	Optionable

FRX, SUPN, PCRX, and NKTR Headlines

Recent News About These Companies

Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High - Here's What Happened

2 hours ago | marketbeat.com

Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock

August 20 at 2:47 AM | benzinga.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Sells $226,840.25 in Stock

August 19 at 4:46 AM | insidertrades.com

Insider Sell: Bethany Sensenig Sells 5,369 Shares of Supernus Pharmaceuticals Inc (SUPN)

August 18 at 6:11 PM | gurufocus.com

Winners And Losers Of Q2: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks

August 18 at 7:51 AM | msn.com

Public Sector Pension Investment Board Purchases 82,167 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

August 16, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Lowers Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

August 14, 2025 | marketbeat.com

Statutory Profit Doesn't Reflect How Good Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are

August 13, 2025 | uk.finance.yahoo.com

5 Insightful Analyst Questions From Supernus Pharmaceuticals’s Q2 Earnings Call

August 13, 2025 | msn.com

SUPN Q2 Deep Dive: Growth Drivers Shift to New Portfolio as Legacy Products Fade

August 13, 2025 | finance.yahoo.com

Here’s Third Avenue Small-Cap Value Fund’s Update on Supernus Pharmaceuticals (SUPN)

August 11, 2025 | insidermonkey.com

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Royalty Pharma (NASDAQ:RPRX)

August 11, 2025 | msn.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Sells $5,882,800.00 in Stock

August 10, 2025 | marketbeat.com

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) CEO Jack A. Khattar Sells 140,000 Shares

August 9, 2025 | insidertrades.com

Supernus Pharmaceuticals Stock Scores RS Rating Upgrade

August 8, 2025 | msn.com

Supernus Pharmaceuticals Scores Relative Strength Rating Upgrade; Hits Key Threshold

August 7, 2025 | msn.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year High on Analyst Upgrade

August 7, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Forecast for Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Price

August 7, 2025 | marketbeat.com

Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results

August 6, 2025 | marketbeat.com

Supernus Pharmaceuticals (SUPN) Price Target Raised by Cantor Fitzgerald | SUPN Stock News

August 6, 2025 | gurufocus.com

Stocks With Rising Relative Strength: Supernus Pharmaceuticals

August 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FRX, SUPN, PCRX, and NKTR Company Descriptions

Forest Road Acquisition NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

Nektar Therapeutics NASDAQ:NKTR

$26.91 +0.19 (+0.70%)

Closing price 03:59 PM Eastern

Extended Trading

$27.08 +0.18 (+0.66%)

As of 04:16 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Pacira BioSciences NASDAQ:PCRX

$25.00 -0.19 (-0.73%)

Closing price 03:59 PM Eastern

Extended Trading

$24.98 -0.02 (-0.08%)

As of 04:10 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Supernus Pharmaceuticals NASDAQ:SUPN

$42.68 +0.68 (+1.63%)

Closing price 03:59 PM Eastern

Extended Trading

$42.68 +0.00 (+0.00%)

As of 04:10 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time